2016 American Transplant Congress
Storage Kidneys Prior to Transplantation Using First Polish Preservation Solution "Biolasol" – Preliminary Report.
One of the factors affecting function of the transplanted organ is a method of its storage. The aim of the study is to evaluate the…2016 American Transplant Congress
Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.
Objective: The aim of this study was to assess if changing between two different formulations of generic tacrolimus ([tac] Mylan® and Dr. Reddy's Lab®) impacts…2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…2016 American Transplant Congress
Excellent Results of Living-Related Renal Transplant Recipients Treated with High-Dose Mizoribine – Comparison of Taclorimus with CsA for Two Years Result by a Japanese Multicenter Study.
Japanese Multicenter Study Group of High Dose Mizoribine in Kidney Transplantation, Kyoto, Japan.
(Aims) Mizoribine (MZR) has been developed as an immunosuppressive agent, but has a less potent immunosuppressive effect up to 3 mg/kg/day. The widespread use of…2016 American Transplant Congress
Post-Trial Experience with Belatacept: A Large Single Center Experience.
Emory Transplant Center, Atlanta, GA.
Evaluation of belatacept in clinical trials revealed significant improvements in renal function and cardiovascular risk leading to superior survival. Despite these proven benefits higher rates…2016 American Transplant Congress
Acute Rejection by Belatacept (Bela) Dosing Frequency: Results from a Phase II Study of Kidney Transplant Recipients.
Background: At 1 year post transplant in IM103-100 (NCT00035555), bela-treated patients had similar acute rejection (AR) rates and significantly improved renal function vs cyclosporine A…2016 American Transplant Congress
Outcomes in Black vs Non-Black Patients Administered Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
Studies consistently show worse outcomes for black vs non-black kidney transplant recipients. At 7 yrs post-transplant in BENEFIT-EXT (NCT00114777), bela was associated with similar graft…2016 American Transplant Congress
Successful Prophylactic Use of Eculizumab in aHUS Kidney Transplant Patients: A Report of 9 Cases.
AHUS is a thrombotic microangiopathy (TMA) triggered by alternate complement pathway (AP) dysregulation. In 60% of patients, a pathogenic variant can be identified in one…2016 American Transplant Congress
Genomic-Derived Markers to Identify Calcineurin Inhibitor Nephrotoxicity in Pediatric Kidney Transplant Recipients.
Background:Calcineurin inhibitor nephrotoxicity (CNIT) is a well-known contributor to chronic allograft dysfunction in kidney transplant recipients (KTRs). Pediatric KTRs are particularly at risk given their…2016 American Transplant Congress
Reduced Incidence and Level of De Novo Donor-Specific Antibodies in Belatacept-Treated vs. Cyclosporine-Treated Patients: Final Results from BENEFIT.
1Emory University, Atlanta, GA; 2Bristol-Myers Squibb, Lawrenceville, NJ.
Background: The presence of donor-specific antibodies (DSA) has been associated with an increased risk of antibody-mediated rejection and graft failure. Mean fluorescence intensity (MFI) is…
American Transplant Congress abstracts